Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 271-278

  Chang, Hyun ^a,b   Rha, Sun Young ^a,b   Jeung, Hei Cheul ^a,b   Im, Chong Kun ^a,b   Noh, Sung Hoon ^b   Kim, Jin Ju ^c   Chung, Hyun Cheol ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

ABCB1 polymorphism; Clinical outcome; Paclitaxel; Stomach cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; PACLITAXEL;

ABCB1 GENE; ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; FEMALE; GENE; GENOTYPE; HUMAN; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM METASTASIS; P-GLYCOPROTEIN; PACLITAXEL; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 76049095127     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000633     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Park DJ and Lenz HJ: Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol 6: 337-344, 2006.
3. Im CK, Jeung HC, Rha SY, Yoo NC, Noh SH, Roh JK and Chung HC: A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemother Pharmacol 61: 315-321, 2008.
4. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK and Chung HC: A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology 70: 63-70, 2006.
5. Marsh S, Somlo G, Li X, et al: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7: 362-365, 2007.
6. Henningsson A, Marsh S, Loos WJ, et al: Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11: 8097-8104, 2005.
7. Clarke R, Leonessa F and Trock B: Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 32: S9-S15, 2005.
8. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A and Mielke S: Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42: 2893-2896, 2006.
9. Tahara T, Arisawa T, Shibata T, Hirata I and Nakano H: Multidrug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol 22: 1678-1682, 2007.
10. + mice. Cancer Res 63: 895-901, 2003.
11. Salama NN, Yang Z, Bui T and Ho RJ: MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 95: 2293-2308, 2006.
12. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54: 1295-1310, 2002.
13. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000.
14. Tanabe M, Ieiri I, Nagata N, et al: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137-1143, 2001.
15. Gréen H, Söderkvist P, Rosenberg P, Horvath G and Peterson C: mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12: 854-859, 2006.
16. Chang H, Rha SY, Jeung HC, et al: Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20: 272-277, 2009.
17. Johne A, Köpke K, Gerloff T, et al: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72: 584-594, 2002.
18. Sissung TM, Baum CE, Deeken J, et al: ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14: 4543-4549, 2008.
19. Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Górnik W and Lubinski J: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 61: 389-394, 2005.
20. Canaparo R, Finnström N, Serpe L and Nordmark A: Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 34: 1138-1144, 2007.
21. Nakamura T, Sakaeda T, Horinouchi M, et al: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71: 297-303, 2002.
22. Nordgard SH, Ritchie MD, Jensrud SD, et al: ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenet Genomics 17: 127-136, 2007.
23. Monden N, Abe S, Hishikawa Y, et al: The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy. Int J Surg Investig 1: 3-10, 1999.
24. Yabuki N, Sakata K, Yamasaki T, et al: Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 173: 1-9, 2007.
25. Lee SS, Kim SY, Kim WY, Thi-Le H, Yoon YR, Yea SS and Shin JG: MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther Drug Monit 27: 531-535, 2005.
26. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485, 2003.
27. Fata F, Ron IG, Kemeny N, O'Reilly E, Klimstra D and Kelsen D: 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86: 1129-1134, 1999.
28. Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 10 (Suppl. 3): 49-58, 2005.
29. Van Triest B, Pinedo HM, Telleman F, van der Wilt CL, Jansen G and Peters GJ: Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem Pharmacol 53: 1855-1866, 1997.